Here's Advertisement
Investment Overview
A MLP offering 9.4% cash distribution yield sounds attractive, and if financial projections see sustained growth in cash distribution, there is a strong case for investment.
This article will discuss why GasLog Partners (NYSE:GLOP) is an attractive MLP to conside
BofI(NASDAQ:BOFI) stock doesn't fit anybody's definition of "cheap."
To be more precise, it's trading at 2.9 times tangible book value (TBV). That's undeniably expensive for any bank; generally, you hope to see that ratio closer to 1.2 to 1.5 times TBV.
But you pay up for quality. H
With a market capitalization of approximately $300 million, our Top Pick among small caps is an under the radar biotech idea, explains Bret Jensen, editor of Investor Alley’s Biotech Gems.
Aratana Therapeutics (PETX) had a good year in 2016 as the shares rose some 60% during the year.
However, the company might have had a better year and one that was not fully reflected....More>>>
Idera Pharmaceuticals Inc. (NASDAQ: IDRA) is focused on cancer and rare diseases, and it could be a what traders refer to as a three-bagger or four-bagger, if two analysts who made key calls in recent days end up being correct here. As it has a market cap of just about $370 million, investors need to consider that they likely are taking far greater risk in Idera than with established biotech and....More>>>
Financial Gravity Companies Inc. raised its stake in shares of Grifols (NASDAQ:GRFS) by 264.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,862 shares of the biotechnology company’s stock after purchasing an additional 10,054 shares during the quarter. Financial Gravity Companies Inc.’s holdings in Grifols were worth $282,000....More>>>
Biotech heavyweight Biogen (NASDAQ:BIIB) has now lost over 13% of its value so far this year. To be fair, this year hasn’t been kind to biotechs in general, thanks to President Trump’s aggressive trade policies with China.But Biogen’s value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS)....More>>>
It has not been a good year for Gilead Sciences (NSDQ:GILD) shareholders. Gilead stock is down bymore than 25% YTD and almost 30% in last one year. The stock has not only heavily underperformed the broader marketbut has also lagged the sector index iShares NASDAQ Biotech Index ETF (NSDQ:IBB) which is down nearly 17% YTD.The poor performance of the stock is mainly caused by declining HCV sales numbers.....More>>>
Sioux City, IA, based Investment company Security National Bank Of So Dak buys Vanguard S&P 500, Vanguard Energy, iShares Nasdaq Biotechnology Index Fund, Vanguard Health Care, US Bancorp, Vanguard Total World Stock Index, iShares Russell 1000 Value, sells General Electric Co, Qualcomm Inc, Nucor Corp, Westinghouse Air Brake Technologies Corp, Alnylam Pharmaceuticals Inc during the 3-months....More>>>
What happened
Shares of Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotech developing vaccines, have risen about 10.7% as of 3:05 p.m. EDT on Thursday. A positive response to the company’s earnings pushed the stock up a couple days ago, but Thursday’s bump comes in response to recent insider share purchases.
So what
Earlier Thursday morning Novavax filed a....More>>>
What happened
Shares ofPuma Biotechnology(NASDAQ:PBYI) are up 44% at 12:12 p.m., having been up as much as 84% today, as investors digest the Food and Drug Administration documentsposted ahead of Wednesday’s advisory committee meeting to review the approvability of Puma’s breast cancer drug neratinib.
So what
Today’s jump wasn’t because of surprisingly....More>>>
Tel-aviv, L3, based Investment company Clal Insurance Enterprises Holdings Ltd buys iShares Nasdaq Biotechnology Index Fund, Orbotech, Perrigo Co PLC, Amdocs, Ormat Technologies Inc, Tower Semiconductor, MarketAxess Holdings Inc, Kornit Digital, Live Nation Entertainment Inc, Verint Systems Inc, sells Vanguard S&P 500, iShares Russell 2000, iShares U.S. Oil & Gas Exploration & Production,....More>>>
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Merck KGaA debuts favorable MS data with a BCR inhibitor
Company:....More>>>
Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.
But there are still plenty of factors that are preventing stocks overall....More>>>
Editor’s note: Seeking Alpha is proud to welcome Biotech Small-Cap Investor as a new contributor. It’s easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Pro. Click here to find out more 禄
I first took a position in Aveo Pharmaceuticals (AVEO) almost 2 years ago, when the stock was less than....More>>>
We write this introduction early Friday, with the fate of the U.S. House of Representatives vote on the American Health Care Act (AHCA) yet to be determined. While any prediction we utter to the result will look stupid soon enough, we can say that this is surely not going to be the end of political discussions that affect the biotech space. Between the continuation of this legislative process, continued....More>>>
Stockholm, V7, based Investment company Rhenman & Partners Asset Management AB buys ACADIA Pharmaceuticals Inc, Gilead Sciences Inc, Sage Therapeutics Inc, AmerisourceBergen Corp, Flexion Therapeutics Inc, Jazz Pharmaceuticals PLC, Esperion Therapeutics Inc, Puma Biotechnology Inc, Agios Pharmaceuticals Inc, Incyte Corp, sells Horizon Pharma PLC, Nektar Therapeutics Inc, Nevro Corp, Aetna Inc,....More>>>
On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:
As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the....More>>>
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
Alnylam results: The only number that really mattersMetric
The next-generation of cholesterol drugs -– compounds that inhibit PCSK-9 -– were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of The Medical Technology Stock
Gene-based therapy is one of the next waves of therapeutic innovation to power this decade and far beyond. The FDA approvals regarding the RNA-based medicines of Sarepta Therapeutics (NASDAQ:SRPT) and the gene-therapy, Luxturna, of Spark Therapeutics (NASDAQ:ONCE) signaled the lowered r
Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:
5/10/2018 – Alnylam Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. Accordin
The next-generation of cholesterol drugs -– compounds that inhibit PCSK-9 -– were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of The Medical Technology Stock
Here's Advertisement